ACI-3024
Alzheimer's Disease / Tauopathies
Phase 1Partnered with Eli Lilly
Key Facts
Indication
Alzheimer's Disease / Tauopathies
Phase
Phase 1
Status
Partnered with Eli Lilly
Company
About AC Immune
Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.
View full company profile